Indivior Inks Pact With Aelis For Cannabis Use Disorder Therapy
AEF0117 Could Be First Approved Drug In Growing Field
A market leader in opioid addiction, Indivior is expanding into the cannabis abuse space which is increasing exponentially due to widespread legalization of recreational use for the drug.
You may also be interested in...
The year to date has been a depressing period for initial public offerings, especially in Europe, but the Madrid-based epigenetics specialist is evaluating whether to head west and list in the US.
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
$600m settlement with DOJ over Suboxone marketing includes corporate integrity agreement and exclusion of subsidiary from government health programs. Indivior also agrees to pay $10m to FTC and be enjoined from future antitrust violations.